GT Biopharma, Inc. (GTBP) › Shares OutstandingGT Biopharma, Inc. (GTBP) — Shares OutstandingAnnual figures by period end, from SEC filings.2010-12-31: 149.57M2011-12-31: 269.30M2012-12-31: 500.57M2013-12-31: 573.05M2014-12-31: 2.37M2015-12-31: 2.40M2016-12-31: 104.2K2017-12-31: 50.12M2018-12-31: 50.65M2019-12-31: 4.10M2020-12-31: 5.22M2021-12-31: 32.06M2022-12-31: 1.09M2023-12-31: 1.38M2024-12-31: 2.23M2025-12-31: 25.53M25.53M2010-12-31Shares Outstanding (shares)2025-12-31Period endedShares OutstandingChange YoYSource filing2025-12-3125.53M+1042.8%2026-03-02Balance as of period end2024-12-312.23M+61.8%2026-03-02Balance as of period end2023-12-311.38M+26.6%2025-02-21Balance as of period end2022-12-311.09M-96.6%2024-03-26Balance as of period end2021-12-3132.06M+514.4%2023-03-30Balance as of period end2020-12-315.22M+27.1%2022-03-28Balance as of period end2019-12-314.10M-91.9%2021-04-16Balance as of period end2018-12-3150.65M+1.1%2020-03-27Balance as of period end2017-12-3150.12M+47989.6%2019-03-29Balance as of period end2016-12-31104.2K-95.7%2018-03-01Balance as of period end2015-12-312.40M+1.4%2018-02-28Balance as of period end2014-12-312.37M-99.6%2018-02-28Balance as of period end2013-12-31573.05M+14.5%2015-03-31Balance as of period end2012-12-31500.57M+85.9%2015-01-08Balance as of period end2011-12-31269.30M+80.0%2014-11-18Balance as of period end2010-12-31149.57M—2012-04-16Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresDividends Per ShareWeighted Average Diluted SharesEPS (Basic)